Dr Hanneke W M van Laarhoven Medische Oncologie

  • Slides: 6
Download presentation
Dr. Hanneke W. M. van Laarhoven Medische Oncologie Academisch Medische Centrum Blik op de

Dr. Hanneke W. M. van Laarhoven Medische Oncologie Academisch Medische Centrum Blik op de toekomst: lopende en geplande DOCG studies • Neoadjuvante chemoradiatie: surgery when needed (pre. SANO) • Neoadjuvante chemoradiatie: targeted treatment (TRAP) • Neoadjuvante/definitieve chemoradiatie: surgery if possible (TOR) • Definitieve chemoradiatie: dosisintensificatie (ART-DECO) • Dataregistratie (POCOP)

pre. SANO pre- Surgery As Needed for Oesophageal carcinoma A single-arm feasibility trial Primary

pre. SANO pre- Surgery As Needed for Oesophageal carcinoma A single-arm feasibility trial Primary endpoint • Correlation between the clinical response during CRE-I and CRE-II and the final pathological response in the resection specimen Secondary endpoints • Serious complications during endoscopic and endosonographic tissue sampling • R 0 -resection rates for all included patients that undergo resection

TRAP Chemoradiation, TRAstuzumab and Pertuzumab in resectable HER 2+ esophageal carcinoma A single arm

TRAP Chemoradiation, TRAstuzumab and Pertuzumab in resectable HER 2+ esophageal carcinoma A single arm feasibility study Primary endpoint • Withdrawal rate from surgery Secondary endpoints • p. CR • Toxicity • Post-operative complications

TOR Chemoradiotherapy followed by resection for patients with gevolgd a T 4 b oesofagus

TOR Chemoradiotherapy followed by resection for patients with gevolgd a T 4 b oesofagus carcinoma Primary endpoint • R 0 resection (≥ 80% ) Secondary endpoints • Post-operative complications • Mortality • Quality of life

ART-DECO A Randomized Trial of Dose Escalation in definitive Chemoradiotherapy for patients with Oesophageal

ART-DECO A Randomized Trial of Dose Escalation in definitive Chemoradiotherapy for patients with Oesophageal cancer Landelijk Platform Radiotherapie voor Gastro Enterologische tumoren Primary endpoint • Local recurrence rate (≥ 15% difference) Secondary endpoints • Grade 3 -4 toxicity • Survival

POCOP Prospective Observational Cohort Study of Oesophageal-gastric cancer Patients Acknowledgments • Joel Shapiro, Bas

POCOP Prospective Observational Cohort Study of Oesophageal-gastric cancer Patients Acknowledgments • Joel Shapiro, Bas Wijnhoven, Jan van Lanschot (pre. SANO) • Maarten Anderegg, Mark van Berge Henegouwen (TOR) • Maarten Hulshof (ART-DECO) • Leonie Haverkamp, Jelle Ruurda (Oesofagus/maag parel)